Viewing nowCombinationTrimeb Duo Controlled-release Tablets 2.5/1000 mg (Linagliptin, Metformin)
Linagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.

MFDS item code 202401578 · Approved 2024.06.28 · Insurance code 622805330
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps improve blood glucose control in patients with type 2 diabetes who are taking linagliptin and metformin together. It can effectively manage blood sugar levels when used alongside meal and exercise therapy. This contributes to alleviating diabetes symptoms and reducing the risk of complications. It supports maintaining a healthy blood glucose level through safe and consistent treatment.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg (linagliptin besylate 6.67mg) and extended-release metformin hydrochloride 2000 mg. This medicine should be taken once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one 5/1000 mg extended-release tablet once daily. Patients taking this medicine as 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine equivalent to the patient's current metformin hydrochloride dose, together with a total daily dose of linagliptin 5mg, should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions, 2. Patients Requiring Caution). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.
This medication is composed of two ingredients, metformin and linagliptin, and is primarily used for the treatment of type 2 diabetes. When taking this medication, special caution is required as a rare but serious condition called lactic acidosis may occur. Lactic acidosis is a dangerous state caused by excessive accumulation of lactic acid in the body, necessitating immediate medical treatment. Patients with allergies to the components in this medicine, type 1 diabetes, severe renal impairment, severe liver dysfunction, acute infections, dehydration, and serious cardiovascular diseases should not take this medication. Additionally, it is advisable for patients with acute or chronic alcohol intoxication, poor nutritional status, or adrenal insufficiency to avoid using this medication. As this medicine can cause hypoglycemia, if taken with other blood glucose-lowering agents or insulin, careful monitoring of hypoglycemia symptoms is imperative. Symptoms of hypoglycemia may include dizziness, cold sweats, and tremors. Patients with reduced renal function may find the excretion of this medication difficult, hence regular renal function tests should be conducted and dosage should be adjusted according to the physician's instructions. This medication should be temporarily discontinued when undergoing surgeries or receiving iodine contrast agents used in radiographic exams, and can be resumed after renal function has returned to normal. Women who are pregnant or planning to become pregnant should avoid using this medication and are advised to control their blood glucose levels using insulin therapy. It is also not safe to use this medication while breastfeeding. Adverse effects such as gastrointestinal disturbances (abdominal pain, diarrhea, nausea, vomiting) may occur, usually improving over time. If severe abdominal pain or persistent symptoms arise, consultation with a physician is necessary. Furthermore, acute pancreatitis or bullous skin disease may occur rarely, so continuous abdominal pain or skin abnormalities should be reported immediately to medical personnel. Vitamin B12 levels may decrease; therefore, it is advisable to regularly check B12 levels through blood tests when using this medication long-term. This medication should be swallowed whole without breaking, chewing, or crushing, and worries about the tablet shell being expelled can be disregarded. When taking other medications simultaneously, potential interactions may occur, so it is essential to inform your physician or pharmacist of any medications currently being taken, and to regularly check blood glucose and renal function. In elderly patients, renal function decline is common, so assessing renal function before administration and adjusting the appropriate dosage is important. In case of overdose, there is a risk of lactic acidosis, so strictly adhere to prescribed doses and visit a medical facility immediately if unusual symptoms develop. Finally, keep this medication out of reach of children and store it in a dry place to avoid moisture.
Severe lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reactions, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemia, taste disturbance, cough, appetite loss, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, itching, erythema, rash, pemphigus-like lesions, severe joint pain associated with disability, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's-type dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscal injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, viral upper respiratory infection, upper respiratory infection, gastroenteritis, vertigo, sensory loss, chest discomfort, weakness, epistaxis, oropharyngeal pain, vocal cord dysfunction, nasal bleeding, androgenetic alopecia, hyperhidrosis, hair loss, dermatitis, anxiety, affective disorder, insomnia, depression, hypertension, hearing loss, erectile dysfunction, goiter, nocturia, dyspepsia, gastroesophageal reflux disease, gastritis, insomnia, confused state, polyuria, vascular disorders, hypotension, flushing, osteoarthritis, limb pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, rotator cuff syndrome, increased serum triglycerides, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase, increased ALT, increased AST, vascular disorders, hypertension, dermatitis, vascular disorders, hypertension
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1°C and 30°C at room temperature. This helps to retain the efficacy and safety of the medication for a longer period.
This medicine is a yellow oval sustained-release film-coated tablet.
30 tablets/bottle, 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
DaiWoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.